Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Gender in Management ; 38(2):255-271, 2023.
Article in English | ProQuest Central | ID: covidwho-2252220

ABSTRACT

PurposeThe purpose of this paper is to interrogate the "double-jeopardy” in widely adopted women's leadership development interventions aimed at "fixing” women, explore critical feminist coaching (CFC) perspectives and practices and offer more equitable and just alternatives for developing women leaders.Design/methodology/approachThis paper includes a literature review of post-feminist and critical feminist perspectives and a critical examination of coaching for women leaders from each perspective.FindingsPostfeminist approaches in organizations are little scrutinized because of the dominant postfeminist discourse that women's subordination and oppression have been "resolved” through neoliberal, individualistic interventions, such as postfeminist coaching programs. Infusing the message of "fixing women” through emphasizing "4 C's” – confidence, control, courage and competition – postfeminist coaching programs have been submitting women leaders to "double jeopardy.” The authors critique this postfeminist coaching paradox from a critical feminist perspective foregrounding "4 R's” – reflecting, reforming, raising and rebuilding – promising more equitable, just development.Originality/valueTo the best of the authors' knowledge, this is the first attempt to describe CFC and presentation of a conceptual and practical model of the process. The authors define postfeminist coaching as the disavowal of feminist values and failure to challenge gender hegemony in the coaching process. The authors propose a model of CFC defined as the explicit embrace of feminist values and challenge of gender hegemony in the coaching process. The authors offer alternatives for developing women leaders amid paradoxical, complex, capitalist systems, with a critical lens challenging postfeminism.

2.
Mediators Inflamm ; 2022: 7137900, 2022.
Article in English | MEDLINE | ID: covidwho-1784924

ABSTRACT

In recent decades, many serious respiratory infections have broken out all over the world, including SARS-CoV, MERS, and COVID-19. They are characterized by strong infectivity, rapid disease progression, high mortality, and poor prognosis. Excessive immune system activation results in cytokine hypersecretion, which is an important reason for the aggravation of symptoms, and can spread throughout the body leading to systemic multiple organ dysfunction, namely, cytokine release syndrome (CRS). Although many diseases related to CRS have been identified, the mechanism of CRS is rarely mentioned clearly. This review is intended to clarify the pathogenetic mechanism of CRS in the deterioration of related diseases, describe the important signaling pathways and clinical pathophysiological characteristics of CRS, and provide ideas for further research and development of specific drugs for corresponding targets to treat CRS.


Subject(s)
COVID-19 , Severe acute respiratory syndrome-related coronavirus , Cytokine Release Syndrome , Humans , Multiple Organ Failure , SARS-CoV-2
3.
Hum Vaccin Immunother ; 18(1): 2040330, 2022 12 31.
Article in English | MEDLINE | ID: covidwho-1758567

ABSTRACT

As an acute respiratory infectious disease, COVID-19 threatens the safety of global public health. Given the current lack of specific treatment against this disease, research and development of vaccines have become sharp weapons for overcoming the pandemic. mRNA vaccines have become the lead in COVID-19 vaccination strategies due to their advantages, such as rapid industrial production and efficacy. A total of 137 COVID-19 vaccines have entered the clinical trial stage, among which 23 are mRNA vaccines, accounting for 17% of the total vaccines. Herein, we summarize the research and developmental processes of mRNA vaccines as well as the approach for protecting the human body against infection. Focusing on the latest clinical trial data of two COVID-19 mRNA vaccines from Pfizer and Modena, we discuss their effectiveness and safety. Finally, we analyze the challenges and problems that mRNA vaccines face in controlling the COVID-19 pandemic.


Subject(s)
COVID-19 , Influenza Vaccines , Influenza, Human , COVID-19/prevention & control , COVID-19 Vaccines , Humans , Influenza, Human/prevention & control , Pandemics/prevention & control , Vaccines, Synthetic , mRNA Vaccines
SELECTION OF CITATIONS
SEARCH DETAIL